Comparision of Radiochemotherapy Applications that Committing with Two Different Chemotherapies Route in Locally Advanced Lung Cancer

Basit Öğe Kaydı
dc.contributor.authorOzmen, Hilal Kiziltunc
dc.contributor.authorSezen, Orhan
dc.contributor.authorAktan, Meryem
dc.contributor.authorErdemci, Burak
dc.contributor.authorAlan, Burcu Saglam
dc.contributor.authorErtekin, Mustafa Vecdi
dc.contributor.authorEzirmik, Sinan
dc.date.accessioned2024-02-23T14:41:05Z
dc.date.available2024-02-23T14:41:05Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractObjective: This study investigated pre- and post-treatment tumor and lymph node dimension response rates and differences between side-effect profiles in patients with locally advanced inoperable nonsmall-cell lung cancer (NSCLC) receiving radiotherapy (RT) and concurrent chemotherapy (CT). Materials and Methods: A total of 30 inoperable patients who had not previously received RT and having a mean age of 58.73 +/- 8.65 years with sufficient hematological reserves and normal hepatic and renal functions were included in the study. Those with pleural effusion, supraventricular lymph node metastasis, and N3 lymph node involvement were excluded. Group I (n=15) received a 21-day 75 mg/m(2) cisplatin (D1) and 15 mg/m(2) vinorelbine (D1, D8), whereas Group II (n=15) received 45 mg/m(2) paclitaxel and AUC2 carboplatin weekly. RT was administered using a linear accelerator device with the 3D conformal RT technique at 6-18 MV energy with a 1.8-2 Gy fraction for 6-7 weeks. Results: Patients were randomized into Group I receiving RT and concurrent cisplatin-vinorelbine and Group II receiving weekly paclitaxel-carboplatin CT. Pre- and post-treatment tumor and lymph node dimensions significantly differed in both groups (p<0.001 and p<0.01, respectively). No significant change was observed in post-RT tumor and lymph node dimensions in terms of applied CT regimens (p>0.05). Conclusion: The significant response achieved with concurrent RT and CT in groups I and II in the local advanced stage of NSCLC is important for local tumor control. Responses to treatment in the group of two arms did not differ.en_US
dc.identifier.doi10.5152/eurasianjmed.2019.19136
dc.identifier.endpage76en_US
dc.identifier.issn1308-8742
dc.identifier.issue1en_US
dc.identifier.pmid32158319en_US
dc.identifier.scopus2-s2.0-85081640883en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage73en_US
dc.identifier.urihttps://doi.org/10.5152/eurasianjmed.2019.19136
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16700
dc.identifier.volume52en_US
dc.identifier.wosWOS:000518179400016en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofEurasian Journal Of Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNon Small Cell Lung Canceren_US
dc.subjectChemotherapyen_US
dc.subjectRadiotherapyen_US
dc.titleComparision of Radiochemotherapy Applications that Committing with Two Different Chemotherapies Route in Locally Advanced Lung Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu